GlassScriptPhysician profile
Robin S Hoebel
NPI 1285780064
$2,282.44
in general payments reported to CMS, 2019-2025
28 companies · $405 in 2025
The $405 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $449 · 2021: $308 · 2022: $374 · 2023: $296 · 2024: $237 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $937.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $282.94 | 2020-2023 | |
| Amgen INC. | $272.81 | 2019-2025 | Evenity, Prolia, Prolia |
| Hologic Sales and Service, LLC | $214.75 | 2020-2025 | Acessa Provu System, Aptima |
| Exeltis, USA INC. | $166.93 | 2019-2023 | Slynd |
| Medical Device Business Services, INC. | $124.99 | 2025 | Enseal |
| Bayer Healthcare Pharmaceuticals INC. | $110.45 | 2020-2023 | |
| Evofem Biosciences, INC. | $101.60 | 2020-2024 | Phexxi |
| Mayne Pharma Commercial LLC | $100.59 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $96.66 | 2023-2025 | Myfembree, Gemtesa |
| Astellas Pharma US INC | $86.02 | 2024-2025 | Veozah |
| Gilead Sciences, INC. | $84.52 | 2022-2023 | |
| Medtronic, INC. | $76.80 | 2023-2025 | Truclear, Ligasure |
| Daiichi Sankyo INC. | $74.53 | 2019-2023 | Injectafer |
| Exact Sciences Corporation | $56.13 | 2023-2025 | Cologuard Collection Kit |
| Organon LLC | $54.99 | 2021-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $53.91 | 2022 | |
| Coopersurgical, INC. | $49.56 | 2019-2020 | |
| Novo Nordisk INC | $47.98 | 2023-2025 | Wegovy |
| Therapeuticsmd, INC. | $43.75 | 2020-2022 | |
| Agile Therapeutics, INC. | $33.99 | 2022-2024 | Twirla |
| Ge Healthcare | $30.88 | 2020 | |
| Boston Scientific Corporation | $23.88 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.13 | 2022 | |
| Biogen, INC. | $18.09 | 2022 | |
| Merck Sharp & Dohme LLC | $17.57 | 2019 | |
| Cepheid | $14.33 | 2023 | |
| Vertical Pharmaceuticals, LLC | $12.85 | 2019 | |
| Vanda Pharmaceuticals INC. | $12.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Hoebel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.